.Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA04_Ranibizumab.Ranibizumab .Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA04_Ranibizumab.Ranibizumab| name: | Ranibizumab |
| ATC code: | S01LA04 | route: | intravitreal |
| n-compartments | 1 |
Ranibizumab is a recombinant, humanized, monoclonal antibody fragment (Fab) that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is primarily used for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Ranibizumab is an approved medication and is widely used in ophthalmology.
Reported pharmacokinetic parameters in adult patients with neovascular AMD after intravitreal injection of 0.5 mg ranibizumab.
Kågedal, M, et al., & Maass, KF (2023). Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age-Related Macular Degeneration. Journal of clinical pharmacology 63(11) 1210–1220. DOI:10.1002/jcph.2290 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37291950
Fidler, M, et al., & Fielder, AR (2020). Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial. Translational vision science & technology 9(8) 43–None. DOI:10.1167/tvst.9.8.43 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32855889
Zhang, Y, et al., & Campochiaro, PA (2014). Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology 121(11) 2237–2246. DOI:10.1016/j.ophtha.2014.05.012 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25001159